Company intelligence / Profile preview

Meilleure Health International

Ownership: Private
Development stage: Other

Overview

Meilleure Health International operates globally as a diversified healthcare group with commercialized offerings in natural health products, CBD cosmetics/supplements, medical devices including Covid‑19 diagnostics, cell therapy services/products, aesthetic medicine services and health management. The company also has significant operations in trading construction materials and renewable energy products. It claims to be the largest hemp producer in China and has expanded into Europe via its Swiss division since at least 2020. No specific clinical trial results are reported.

Therapeutic areas: OtherInfectious Diseases
Modalities: Cell therapyCBD-based productsMedical devicesSupplementsSmall molecule
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Meilleure Health International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meilleure Health International.

Explore the full profile